Log in

ASX:FTTFactor Therapeutics Stock Price, Forecast & News

Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume425,600 shs
Average Volume433,334 shs
Market Capitalization$4.17 million
P/E RatioN/A
Dividend YieldN/A
Factor Therapeutics Limited, a clinical stage biotechnology company, develops treatments for wound care and healing. The company was formerly known as Tissue Therapies Limited and changed its name to Factor Therapeutics Limited in May 2016. Factor Therapeutics Limited is headquartered in Brisbane, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.54 out of 5 stars

Industry, Sector and Symbol

Industry Biotechnology



Sales & Book Value

Annual Sales$2.49 million
Book ValueA$0.00 per share



Outstanding Shares1,042,840,000
Market Cap$4.17 million
Next Earnings DateN/A
OptionableNot Optionable

Receive FTT News and Ratings via Email

Sign-up to receive the latest news and ratings for FTT and its competitors with MarketBeat's FREE daily newsletter.

Factor Therapeutics (ASX:FTT) Frequently Asked Questions

How were Factor Therapeutics' earnings last quarter?

Factor Therapeutics Ltd (ASX:FTT) released its earnings results on Thursday, August, 8th. The biotechnology company reported $0.00 earnings per share for the quarter. View Factor Therapeutics' earnings history.

Has Factor Therapeutics been receiving favorable news coverage?

Media stories about FTT stock have trended negative on Saturday, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Factor Therapeutics earned a news impact score of -2.4 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news about Factor Therapeutics.

Who are some of Factor Therapeutics' key competitors?

Who are Factor Therapeutics' key executives?

Factor Therapeutics' management team includes the following people:
  • Dr. Rosalind Wilson MBBS, MBA, Consultant
  • Ms. Melanie Farris, Company Sec.

What is Factor Therapeutics' stock symbol?

Factor Therapeutics trades on the ASX under the ticker symbol "FTT."

How big of a company is Factor Therapeutics?

Factor Therapeutics has a market capitalization of $0.00 and generates $2.49 million in revenue each year.

What is Factor Therapeutics' official website?

The official website for Factor Therapeutics is factor-therapeutics.com.

How can I contact Factor Therapeutics?

Factor Therapeutics' mailing address is L 19 179 Turbot St, BRISBANE, QLD 4000, Australia. The biotechnology company can be reached via phone at +61-7-33343900.

This page was last updated on 7/4/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.